- Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model
-
Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel
- Shen, Sida,Picci, Cristina,Ustinova, Kseniya,Benoy, Veronick,Kutil, Zsófia,Zhang, Guiping,Tavares, Maurício T.,Pavlí?ek, Ji?í,Zimprich, Chad A.,Robers, Matthew B.,Van Den Bosch, Ludo,Ba?inka, Cyril,Langley, Brett,Kozikowski, Alan P.
-
p. 4810 - 4840
(2021/05/07)
-
- A scalable and safe continuous flow procedure for in-line generation of diazomethane and its precursor MNU
-
Diazomethane is a valuable C1-building block for organic synthesis. Due to its intrinsic reactivity and instability, handling of this reagent is associated with serious safety hazards. Herein we present a simple and robust continuous flow process, allowing a safe and on-demand generation of diazomethane with a productivity of 95-117 mmol h-1. The developed two-step process starts from non-hazardous N-methylurea, and generates and consumes N-methyl-N-nitrosourea (MNU) and diazomethane, thus enabling a safe and convenient scale-up to a multi-gram scale in a conventional synthesis laboratory.
- Lehmann
-
supporting information
p. 1449 - 1453
(2017/05/10)
-
- TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
-
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, tr
- -
-
Paragraph 0176-0177
(2017/09/08)
-
- 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same.
- -
-
Paragraph 00570-00572
(2017/10/06)
-
- Synthesis of novel 3-substituted benzamides related to imatinib
-
Twelve new 3-substituted benzamide derivatives structurally related to tyrosine kinase inhibitor imatinib have been synthesised by a Cu(I)-catalysed coupling of three previously synthesised (5-iodo-2-methylphenyl)-[4-(pyridin-3-yl)-6-perfluoroalkylpyrimidin-2-yl]amines with four synthesised 3-substituted 4-(4-methylpiperazin-1-ylmethyl)benzamides.
- Terentjeva, Svetlana,Muceniece, Dzintra,Petushkova, Jekaterina,Lusis, Viesturs
-
p. 224 - 227
(2016/05/11)
-
- Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography
-
Increased activity of efflux transporters, e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), at the blood-brain barrier is a pathological hallmark of many neurological diseases, and the resulting multiple drug resistance represents a major clinical challenge. Noninvasive imaging of transporter activity can help to clarify the underlying mechanisms of drug resistance and facilitate diagnosis, patient stratification, and treatment monitoring. We have developed a metabolically activated radiotracer for functional imaging of P-gp/BCRP activity with positron emission tomography (PET). In preclinical studies, the tracer showed excellent initial brain uptake and clean conversion to the desired metabolite, although at a sluggish rate. Blocking with P-gp/BCRP modulators led to increased levels of brain radioactivity; however, dynamic PET did not show differential clearance rates between treatment and control groups. Our results provide proof-of-concept for development of prodrug tracers for imaging of P-gp/BCRP function in vivo but also highlight some challenges associated with this strategy.
- Sander, Kerstin,Galante, Eva,Gendron, Thibault,Yiannaki, Elena,Patel, Niral,Kalber, Tammy L.,Badar, Adam,Robson, Mathew,Johnson, Sean P.,Bauer, Florian,Mairinger, Severin,Stanek, Johann,Wanek, Thomas,Kuntner, Claudia,Kottke, Tim,Weizel, Lilia,Dickens, David,Erlandsson, Kjell,Hutton, Brian F.,Lythgoe, Mark F.,Stark, Holger,Langer, Oliver,Koepp, Matthias,?rstad, Erik
-
p. 6058 - 6080
(2015/08/24)
-
- PROTEIN KINASE INHIBITORS
-
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.
- -
-
Page/Page column 44-45
(2014/07/21)
-
- AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS
-
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.
- -
-
Page/Page column 49
(2014/07/21)
-
- AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
-
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus a
- -
-
Page/Page column 48-49
(2014/07/21)
-
- NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.
- -
-
Paragraph 0615
(2013/10/22)
-
- ADAMANTYL COMPOUNDS
-
The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are
- -
-
Page/Page column 53
(2012/10/18)
-
- NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.
- -
-
Page/Page column 82
(2012/06/30)
-
- NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS
-
The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
- -
-
Page/Page column 56
(2011/09/15)
-
- A practical synthesis of a diazepinylbenzoic acid, a retinoid X receptor antagonist
-
An optimized convergent synthetic route for the preparation of retinoid X receptor (RXR) antagonist (1) in an overall yield of 35% is described. The formation of the benzodiazepine was achieved in 85% yield using POCl3 in toluene. The drug subs
- Jiang, Xinglong,Lee, George T.,Prasad, Kapa,Repic, Oljan
-
p. 1137 - 1141
(2013/01/03)
-
- IMIDAZOPYRIDINE COMPOUND
-
The present invention provides an imidazopyridine compound represented by formula (I), wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents -(CH2)m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.
- -
-
Page/Page column 40
(2008/06/13)
-
- VASOPRESSIN V1A ANTAGONISTS
-
The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V 1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.
- -
-
Page/Page column 29
(2008/06/13)
-
- Piperazines as oxytocin agonists
-
Disclosed are novel compounds according to general formula I, which have shown OT agonist activity.
- -
-
Page/Page column 11
(2010/02/11)
-
- benzamide derivatives as oxytocin agonists and vasopressin antagonists
-
Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.
- -
-
-
- NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF
-
A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.
- -
-
Page 123-124
(2010/02/07)
-
- Superoxide dismutase mimetics: synthesis and structure-activity relationship study of MnTBAP analogues.
-
Carboxylic ester and amide-substituted analogues of [5,10,15,20-tetrakis(4-carboxyphenyl)-porphyrinato]manganese(III) chloride (MnTBAP) were synthesized and assayed as potential superoxide dismutase (SOD) mimetics. The tetraester analogues 4a and 4b were
- Gauuan, Polivina Jolicia F,Trova, Michael P,Gregor-Boros, Livia,Bocckino, Stephen B,Crapo, James D,Day, Brian J
-
p. 3013 - 3021
(2007/10/03)
-
- Rearrangement and radical mediated decarboxylation of trimethylsilyl benzoates using xenon difluoride
-
Treatment of trimethylsilyl benzoates 1 with xenon difluoride in CH2Cl2 or C6F6 results in a novel ester rearrangement and formation of aryl fluoroformates 2: rearrangement is not observed in MeCN solution in wh
- Nongkunsarn, Pakawan,Ramsden, Christopher A.
-
p. 121 - 122
(2007/10/03)
-